Basel Kosten Effektivitäts Trial – SAphenous Venous Graft Angioplasty Using Glycoprotein 2b/3a Receptor Inhibitors and Drug-Eluting Stents - BASKET-SAVAGE
Contribution To Literature:
The BASKET-SAVAGE trial showed that drug-eluting stents reduce major adverse cardiac events in saphenous vein graft lesions.
The goal of the trial was to evaluate percutaneous coronary intervention (PCI) with a drug-eluting stent compared with a bare-metal stent among patients with a saphenous vein graft (SVG) lesion.
Patients with a saphenous vein graft (SVG) lesion were randomized to a drug-eluting stent (Taxus Liberte; n = 89) versus a bare-metal stent (Liberte; n = 84). All patients were recommended to receive a glycoprotein IIb/IIIa inhibitor and a distal protection device (FilterWire) during PCI.
- Patients with SVG stenosis undergoing PCI
- Total number of enrollees: 173
- Duration of follow-up: 36 months
- Mean patient age: 72 years
The trial was terminated early due to slow enrollment.
The primary outcome, incidence of cardiac death, nonfatal myocardial infarction, or target vessel revascularization at 12 months, occurred in 2.3% of the drug-eluting stent group versus 17.9% of the bare-metal stent group (p < 0.001). The association remained the same in longer-term follow-up.
- Stent thrombosis: 0 versus 4.8% (p = 0.09); respectively, for drug-eluting versus bare-metal stents
- Major bleeding: 2.3% versus 2.4% (p = 0.91); respectively, for drug-eluting versus bare-metal stents
Among patients with a SVG lesion, the use of a drug-eluting stent was associated with a reduction in major adverse events compared with a bare-metal stent. The risk of stent thrombosis and major bleeding were the same between treatment groups. The results of the DIVA trial are awaited.
Presented by Dr. Raban Jeger at the European Society of Cardiology Congress, Rome, Italy, August 30, 2016.
< Back to Listings